| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
1999-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8f877d3c45777325d06ad5e65a574bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed8e4d054e7e9e0d3a649d44c302e2af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2f90c3630fa118a74f4aad0a9f29a6e |
| publicationDate |
1999-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9966958-A2 |
| titleOfInvention |
Use of a compound having affinity for the benzodiazepine mitochondrial receptor in cancer therapy |
| abstract |
The invention concerns in particular a combination product comprising at least a compound having affinity for the benzodiazepine mitochondrial receptor and at least an apoptosis-inducing agent for simultaneous, separate or sustained use, for treating cancer. The invention also concerns the use of said compound and/or said combination product for making a medicine particularly for facilitating apoptosis induction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7683046-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1423122-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7638624-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2808197-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1423122-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9849138-B2 |
| priorityDate |
1998-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |